George Schlich
Patent Attorney & Director
George Schlich is a UK and European Patent Attorney, a founding director and shareholder of ONK Therapeutics and has been responsible from the start for the IP portfolio.
His firm specialises in patents in the chemical and biochemical fields and represents inter alia US companies Intellia Therapeutics, Inc in relation to CRISPR/Cas9 and AbbVie Inc in relation to oncology. George has represented clients in preparation for listing on UK’s AIM and NASDAQ, US and for the Singapore stock market.
George received his MA(Natural Sciences) from Cambridge University, UK, specialising in biology of cells, chemistry, pathology, physiology, mathematics, pharmacology, and history and philosophy of science.
